124 related articles for article (PubMed ID: 27449755)
1. Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications.
Palomo AG; Santana RB; Pérez XE; Santana DB; Gabri MR; Monzon KL; Pérez AC
Clin Exp Metastasis; 2016 Oct; 33(7):717-25. PubMed ID: 27449755
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody.
Hernández AM; Toledo D; Martínez D; Griñán T; Brito V; Macías A; Alfonso S; Rondón T; Suárez E; Vázquez AM; Pérez R
J Immunol; 2008 Nov; 181(9):6625-34. PubMed ID: 18941253
[TBL] [Abstract][Full Text] [Related]
3. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism.
Hernández AM; Rodríguez N; González JE; Reyes E; Rondón T; Griñán T; Macías A; Alfonso S; Vázquez AM; Pérez R
J Immunol; 2011 Mar; 186(6):3735-44. PubMed ID: 21300821
[TBL] [Abstract][Full Text] [Related]
4. N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese.
Zhong Y; Wu Y; Li C; Tang J; Wang X; Ren G; Carr A; Pérez R; Guo W
Oral Dis; 2012 Nov; 18(8):741-7. PubMed ID: 22574836
[TBL] [Abstract][Full Text] [Related]
5. Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.
Labrada M; Clavell M; Bebelagua Y; León Jd; Alonso DF; Gabri MR; Veloso RC; Vérez V; Fernández LE
Expert Opin Biol Ther; 2010 Feb; 10(2):153-62. PubMed ID: 20088712
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of N-glycolyl GM3 ganglioside is associated with the aggressive biological behavior of human sarcomas.
Pilco-Janeta D; De la Cruz Puebla M; Soriano J; Osorio M; Caballero I; Pérez AC; Savon L; Cremades N; Blanco R; Carr A
BMC Cancer; 2019 Jun; 19(1):556. PubMed ID: 31182063
[TBL] [Abstract][Full Text] [Related]
7. Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties.
Rodríguez-Zhurbenko N; Martínez D; Blanco R; Rondón T; Griñán T; Hernández AM
Eur J Immunol; 2013 Mar; 43(3):826-37. PubMed ID: 23319307
[TBL] [Abstract][Full Text] [Related]
8. Anti-NeuGcGM3 reactivity: a possible role of natural antibodies and B-1 cells in tumor immunosurveillance.
Rodriguez-Zhurbenko N; Rabade-Chediak M; Martinez D; Griñan T; Hernandez AM
Ann N Y Acad Sci; 2015 Dec; 1362():224-38. PubMed ID: 26214505
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences.
Blanco R; Domínguez E; Morales O; Blanco D; Martínez D; Rengifo CE; Viada C; Cedeño M; Rengifo E; Carr A
Patholog Res Int; 2015; 2015():132326. PubMed ID: 26634172
[TBL] [Abstract][Full Text] [Related]
10. Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy.
Valdes-Zayas A; Gonzalez Z; Mulens V; Vega AM; Perez K; Lorenzo-Luaces P; Rubio MC; Estevez A; Curbelo I; Fernandez LE; Crombet T; Mazorra Z
J Immunother; 2017 Oct; 40(8):289-301. PubMed ID: 28604556
[TBL] [Abstract][Full Text] [Related]
11. Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer.
Johnstone CN; Smith YE; Cao Y; Burrows AD; Cross RS; Ling X; Redvers RP; Doherty JP; Eckhardt BL; Natoli AL; Restall CM; Lucas E; Pearson HB; Deb S; Britt KL; Rizzitelli A; Li J; Harmey JH; Pouliot N; Anderson RL
Dis Model Mech; 2015 Mar; 8(3):237-51. PubMed ID: 25633981
[TBL] [Abstract][Full Text] [Related]
12. Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients.
Segatori VI; Cuello HA; Gulino CA; Albertó M; Venier C; Guthmann MD; Demarco IA; Alonso DF; Gabri MR
Cancer Immunol Immunother; 2018 Aug; 67(8):1285-1296. PubMed ID: 29936534
[TBL] [Abstract][Full Text] [Related]
13. Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3.
Palomo AG; Medinilla AL; Segatori V; Barroso MDC; Blanco R; Gabri MR; Pérez AC; Monzón KL
Oncotarget; 2018 May; 9(35):24069-24080. PubMed ID: 29844873
[TBL] [Abstract][Full Text] [Related]
14. Induction of Glycosphingolipid GM3 Expression by Valproic Acid Suppresses Cancer Cell Growth.
Kawashima N; Nishimiya Y; Takahata S; Nakayama KI
J Biol Chem; 2016 Oct; 291(41):21424-21433. PubMed ID: 27539856
[TBL] [Abstract][Full Text] [Related]
15. Endogenously produced ganglioside GM3 endows etoposide and doxorubicin resistance by up-regulating Bcl-2 expression in 3LL Lewis lung carcinoma cells.
Noguchi M; Kabayama K; Uemura S; Kang BW; Saito M; Igarashi Y; Inokuchi J
Glycobiology; 2006 Jul; 16(7):641-50. PubMed ID: 16571667
[TBL] [Abstract][Full Text] [Related]
16. Ganglioside GM3 inhibits hepatoma cell motility via down-regulating activity of EGFR and PI3K/AKT signaling pathway.
Huang X; Li Y; Zhang J; Xu Y; Tian Y; Ma K
J Cell Biochem; 2013 Jul; 114(7):1616-24. PubMed ID: 23355442
[TBL] [Abstract][Full Text] [Related]
17. Control of cell motility by interaction of gangliosides, tetraspanins, and epidermal growth factor receptor in A431 versus KB epidermoid tumor cells.
Park SY; Yoon SJ; Freire-de-Lima L; Kim JH; Hakomori SI
Carbohydr Res; 2009 Aug; 344(12):1479-86. PubMed ID: 19559406
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine.
Carr A; Rodríguez E; Arango Mdel C; Camacho R; Osorio M; Gabri M; Carrillo G; Valdés Z; Bebelagua Y; Pérez R; Fernández LE
J Clin Oncol; 2003 Mar; 21(6):1015-21. PubMed ID: 12637465
[TBL] [Abstract][Full Text] [Related]
19. Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms.
Garrido G; Rabasa A; Garrido C; López A; Chao L; García-Lora AM; Garrido F; Fernández LE; Sánchez B
Oncogene; 2014 Jun; 33(24):3129-39. PubMed ID: 23975426
[TBL] [Abstract][Full Text] [Related]
20. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.
Alfonso S; Valdés-Zayas A; Santiesteban ER; Flores YI; Areces F; Hernández M; Viada CE; Mendoza IC; Guerra PP; García E; Ortiz RA; de la Torre AV; Cepeda M; Pérez K; Chong E; Hernández AM; Toledo D; González Z; Mazorra Z; Crombet T; Pérez R; Vázquez AM; Macías AE
Clin Cancer Res; 2014 Jul; 20(14):3660-71. PubMed ID: 24788102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
